Short Interest in Novo Nordisk A/S (NYSE:NVO) Decreases By 14.9%

Novo Nordisk A/S (NYSE:NVO) was the target of a significant decline in short interest during the month of February. As of February 13th, there was short interest totaling 26,973,270 shares, a decline of 14.9% from the January 29th total of 31,693,294 shares. Based on an average daily volume of 30,479,797 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the company’s stock are short sold. Approximately 0.6% of the company’s stock are short sold. Based on an average daily volume of 30,479,797 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. True Wealth Design LLC increased its position in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $25,000. WealthCollab LLC lifted its stake in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares in the last quarter. Finally, American National Bank & Trust acquired a new position in Novo Nordisk A/S during the fourth quarter worth about $28,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the subject of a number of recent analyst reports. HSBC reissued a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. The Goldman Sachs Group restated a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Five analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $53.93.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised Novo Nordisk to an “Equal Weight” rating, which can stabilize sentiment and attract buyers who follow MS coverage. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Positive Sentiment: Market reaction: some reports note a share bump after the FDA crackdown targeted telehealth GLP‑1 advertisers — investors may view tighter enforcement of competitors/third‑party marketers as reducing unfair competition and supporting incumbents like Novo. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Neutral Sentiment: Goldman Sachs reaffirmed a “Neutral” rating — maintenance of status quo from a major shop, limited immediate catalyst. The Goldman Sachs Group Reaffirms “Neutral” Rating for Novo Nordisk A/S (NYSE:NVO)
• Neutral Sentiment: Analyst/market commentary continues a valuation debate (some see oversold risk, others await clearer catalysts) — this keeps the stock in focus but implies mixed conviction. Novo Nordisk (NYSE:NVO) Valuation Debate Lingers As Market Awaits Catalyst Clarity
• Negative Sentiment: Regulatory risk rose: the U.S. FDA issued a second warning letter telling Novo to stop running a consumer Ozempic ad it deems false/misleading. This increases the risk of ad pulls, reputational damage and closer FDA scrutiny of GLP‑1 marketing. US FDA warns Novo for second time about misleading Ozempic advertising
• Negative Sentiment: Investor litigation risk: Pomerantz LLP opened an investor investigation into Novo Nordisk, signaling potential class‑action exposure tied to the recent controversies. Legal risk can lead to expenses and reputational impact. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Policy/market access pressure: the American Hospital Association urged HRSA to block Novo’s new claims‑data submission policy for 340B hospitals — may strain hospital relationships and affect access/negotiations in the U.S. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded up $0.52 during trading hours on Thursday, hitting $39.02. The company’s stock had a trading volume of 20,549,628 shares, compared to its average volume of 26,809,383. The stock has a market cap of $174.22 billion, a PE ratio of 11.24 and a beta of 0.73. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $89.03. The company has a 50 day moving average of $51.96 and a 200 day moving average of $52.58. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is presently 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.